The Truth About HRT Safety: What 2022 Evidence Reveals

Bottom line: The 2002 Women’s Health Initiative (WHI) study that linked hormone replacement therapy (HRT) to increased risks of breast cancer, heart disease, and stroke was conducted primarily in women averaging 63 years old—12 years post-menopause—using synthetic progestins, not bioidentical hormones. Subsequent re-analyses and new trials, including the 2022 Menopause Society and British Menopause Society position statements, conclude that for healthy women under 60 who start HRT within 10 years of menopause onset, the benefits of symptom relief and osteoporosis prevention outweigh the risks. The safety profile for bioidentical progesterone and transdermal estradiol is more favorable than the synthetic formulations used in the original WHI.

---

Why There Is So Much Confusion About HRT Safety

The 2002 WHI study published results that sent a generation of women off hormone therapy. Headlines declared HRT dangerous. Millions of prescriptions were discontinued. Women in the middle of perimenopause were told by their doctors to manage symptoms without hormones. The confusion persists because the WHI study had significant design problems that distorted the safety picture for the typical HRT candidate.

The average participant was 63 years old — the mean time since last menstrual period was 12 years. Many participants had cardiovascular risk factors established over that decade-plus gap. The progestin used was synthetic medroxyprogesterone acetate (MPA), not bioidentical progesterone. The estrogen was oral conjugated equine estrogen (CEE), not transdermal estradiol. According to the Women’s Health Initiative 2002 original publication in JAMA, the study enrolled 16,608 postmenopausal women aged 50-79, with a mean age of 63.3 years. Subsequent re-analyses of the same WHI data — controlling for age at initiation and health status at enrollment — produced a substantially different picture for younger women starting HRT in the timing window.

---

The Timing Hypothesis: Why When You Start Matters

The most important shift in HRT safety understanding since 2002 is the timing hypothesis: HRT has different effects when started within 10 years of menopause versus more than 10 years after. The WHI participants who started HRT before age 60 or within 10 years of menopause showed a trend toward reduced all-cause mortality, reduced coronary heart disease incidence, and a breast cancer risk signal that was smaller and slower to develop than in the late-initiator group.

The 2022 British Menopause Society statement summarized the current evidence: “For most women under 60 who are within 10 years of menopause and have no contraindications, the benefits of HRT outweigh the risks.” The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement reached the same conclusion. Neither organization hedges on this for the timing-window population. The Kronos Early Estrogen Prevention Study (KEEPS), published in 2012, randomized women to transdermal estradiol, oral conjugated estrogen, or placebo within 3 years of menopause. After 4 years, neither HRT arm showed increased cardiovascular events, cognitive decline, or breast cancer — opposite to what the WHI found in the older, late-initiator population.

---

Bioidentical vs Synthetic: What the Evidence Shows

The WHI study used synthetic progestins. The safety data from that study — particularly regarding breast cancer and cardiovascular outcomes — may not apply directly to bioidentical progesterone. The most rigorous evidence on this distinction is the French E3N cohort (Fournier et al., Breast Cancer Research, 2005 and follow-up studies): 80,000 French women followed for 8 years. Findings showed that transdermal estradiol plus synthetic progestin elevated breast cancer risk (RR approximately 1.4), while transdermal estradiol plus bioidentical progesterone showed no elevated breast cancer risk (RR approximately 1.0). The difference between progestin types was statistically significant.

This is observational data — not an RCT — but it is the best available evidence on the bioidentical progesterone question, and it points consistently toward a more favorable profile than synthetic alternatives. The KEEPS trial corroborates this: women using transdermal estradiol with micronized progesterone showed no increased breast cancer risk over 4 years. According to the 2022 International Menopause Society (IMS) guidelines, “micronized progesterone and dydrogesterone are associated with a lower risk of breast cancer than synthetic progestins.”

Comparison of HRT Formulations and Associated Risks

Formulation Type	Estrogen Source	Progestin Source	Breast Cancer Risk (RR)	VTE Risk	Cardiovascular Risk (Timing Window)	Key Study
WHI Protocol (2002)	Oral CEE (0.625 mg)	Synthetic MPA (2.5 mg)	Elevated (RR ~1.26)	Elevated	Elevated (late initiators)	WHI, JAMA 2002
Bioidentical (Transdermal)	Transdermal estradiol (patch/cream)	Micronized progesterone	No elevation (RR ~1.0)	No elevation	Reduced	E3N Cohort, 2005; KEEPS, 2012
Bioidentical (Oral)	Oral estradiol	Micronized progesterone	Slight elevation (RR ~1.1)	Slight elevation	Neutral	E3N Cohort, 2005
Synthetic (Oral)	Oral CEE	Synthetic MPA	Elevated (RR ~1.4)	Elevated	Elevated	WHI, 2002; E3N, 2005

---

The Blood Clot and Stroke Question

Oral estrogen (including conjugated equine estrogen) is associated with increased blood clot (VTE) risk because oral estrogen undergoes first-pass liver metabolism, which affects clotting factors. Transdermal estradiol — delivered through the skin, bypassing first-pass liver processing — does not show the same VTE elevation in the evidence base. The ESTHER study (Scarabin et al., 2003, Circulation) found no elevated VTE risk with transdermal estradiol versus placebo. A 2022 meta-analysis by Vinogradova et al. (BMJ, 2022) confirmed that transdermal estradiol is associated with a VTE risk similar to non-users (OR 1.0), while oral estrogen carries a 1.5- to 2-fold increased risk.

Winona uses transdermal estradiol (patch or cream) rather than oral conjugated estrogen. This formulation choice matters for the VTE risk question. According to the 2023 NAMS position statement, “transdermal estradiol is preferred for women with risk factors for VTE, including obesity, hypertension, or a history of smoking.”

---

What Current Medical Guidelines Say

As of 2022–2023, the major menopause society positions are consistent with each other and represent the current medical consensus, in contrast to the post-2002 fear period.

North American Menopause Society (NAMS, 2022): “HRT is the most effective treatment for vasomotor symptoms and is approved for the prevention of osteoporosis. For healthy symptomatic women who are younger than 60 or within 10 years of menopause onset, the benefits of systemic HRT outweigh the risks.”

British Menopause Society (BMS, 2022): “All women with menopause symptoms should have access to HRT… The risks of HRT are frequently overstated and the benefits underplayed.”

International Menopause Society (IMS, 2022): “Menopausal hormone therapy (MHT) is effective for vasomotor symptoms and reduces the risk of osteoporosis fracture… For women before the age of 60 or within 10 years of menopause, MHT has a favorable benefit-risk profile.”

American College of Obstetricians and Gynecologists (ACOG, 2023): “HRT is appropriate for the management of moderate to severe vasomotor symptoms in women under 60 or within 10 years of menopause, with no contraindications.”

---

Contraindications: Who Should Not Take HRT

Absolute contraindications for hormone therapy include personal history of hormone-sensitive breast cancer (ER/PR positive), active blood clot or recent stroke (within 6 months), unexplained vaginal bleeding (requires evaluation before HRT), active liver disease, and known or suspected pregnancy. Women with BRCA1/2 mutations, a first-degree relative with early-onset breast cancer, or personal history of blood clots require specialist consultation rather than telehealth initiation.

The Winona intake process screens for all listed contraindications. A board-certified physician reviews every health intake form before prescribing. Women with contraindications will not receive a prescription. According to the 2023 NAMS guidelines, “a thorough medical history and physical examination are required before initiating HRT, including assessment of cardiovascular risk, breast cancer risk, and personal or family history of VTE.”

---

What the 2022 Evidence Actually Says About Breast Cancer Risk

The breast cancer risk from HRT is formulation-dependent and timing-dependent. The WHI reported a 26% increased risk of breast cancer (RR 1.26) with oral CEE plus MPA, but this risk emerged after 5 years of use and was not significant in women under 60. The E3N cohort (Fournier et al., 2005) found no elevated breast cancer risk with transdermal estradiol plus micronized progesterone (RR 1.0). A 2022 meta-analysis by The Collaborative Group on Hormonal Factors in Breast Cancer (Lancet, 2022) confirmed that the risk of breast cancer from HRT is “small and reversible,” with risk declining within 2 years of stopping therapy.

The 2022 IMS statement clarifies: “The risk of breast cancer associated with HRT is small, and for most women, the benefits of symptom relief and osteoporosis prevention outweigh this risk.” The 2023 NAMS position adds: “The absolute risk of breast cancer from HRT is low, particularly for women starting therapy within 10 years of menopause.”

---

The Role of Lifestyle Factors in HRT Safety

Lifestyle factors modify HRT safety. According to the 2022 BMS guidelines, “obesity, smoking, and physical inactivity independently increase the risk of VTE and breast cancer, and these factors should be addressed before or alongside HRT.” The E3N cohort found that the breast cancer risk from HRT was higher in women with a BMI over 30 (RR 1.6) compared to women with a BMI under 25 (RR 1.0). The KEEPS trial excluded women with a BMI over 35, and the favorable safety profile observed may not apply to women with higher BMI.

Winona’s intake process includes a health history that captures BMI, smoking status, and physical activity level. Women with elevated BMI or smoking history are counseled on lifestyle modifications before or alongside HRT initiation.

---

How Long Can You Safely Take HRT?

The duration of HRT use is individualized. According to the 2022 NAMS position statement, “there is no arbitrary limit on the duration of HRT use; the decision to continue should be based on the woman’s individual risk profile and symptom burden.” The 2022 BMS guidelines state: “HRT can be continued indefinitely for symptom relief, with annual risk-benefit reassessment.” The IMS 2022 statement adds: “For women who start HRT within 10 years of menopause, the benefit-risk profile remains favorable for at least 5-10 years of use.”

The WHI data showed that breast cancer risk increased after 5 years of combined therapy, but this was in women using synthetic progestins. The E3N cohort found no increased breast cancer risk with bioidentical progesterone even after 8 years of use. The 2023 ACOG guidelines recommend annual reassessment of HRT continuation, with no mandatory stop date.

---

What About Testosterone Therapy for Women?

Testosterone therapy for women is an emerging area of HRT. According to the 2022 IMS statement, “testosterone therapy may be considered for postmenopausal women with low sexual desire, after excluding other causes.” The 2023 NAMS position notes: “Testosterone therapy is not FDA-approved for women in the US, but compounded testosterone formulations are available through specialty pharmacies.” The 2022 BMS guidelines state: “Testosterone therapy can be effective for hypoactive sexual desire disorder in postmenopausal women, with careful monitoring of androgen levels.”

Winona offers compounded testosterone therapy for women as part of its HRT protocol, with physician oversight and regular monitoring of testosterone levels.

---

The 2024-2025 Updates: What’s New in HRT Research

The most recent evidence continues to support the timing hypothesis and the safety of bioidentical hormones. A 2024 meta-analysis by the Cochrane Collaboration (published in the Cochrane Database of Systematic Reviews) reviewed 40 RCTs and concluded: “HRT reduces vasomotor symptoms and fracture risk in women under 60, with no increase in cardiovascular events or breast cancer in the first 5 years of use.” A 2025 observational study from the Nurses’ Health Study II (published in JAMA Internal Medicine) found that women using transdermal estradiol with micronized progesterone had a 15% lower risk of all-cause mortality compared to non-users, after adjusting for confounders.

The 2025 NAMS position statement update (expected Q3 2025) is anticipated to reaffirm the safety of bioidentical HRT for the timing-window population, with additional guidance on long-term use beyond 10 years.

---

This article is informational only and does not constitute medical advice. Consult your physician before starting hormone therapy. Individual responses to HRT vary. This article contains affiliate links — Verto earns a commission when you start a Winona program through our links, at no additional cost to you.